Home / Research / Publications / Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors does age matter

Publications

Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors does age matter

Background

  • HCC is associated with significant geriatric comorbidities, with the median age of diagnosis being 65 years.
  • Further, multi-kinase inhibitors (MKIs) are associated with up to 60% of grade 3-4 toxicities. 
  • While not an independent risk factor, age significantly influences patient outcomes.
  • We aim to analyze the association of survival with age in HCC and identify molecular markers associated with survival in older patients with HCC receiving TKIs.
Download Publication
Learn More
Name(Required)